National Bank of Canada’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21M Sell
63,607
-2,826
-4% -$962K 0.02% 480
2025
Q4
$26.4M Buy
66,433
+65,476
+6,842% +$29M 0.02% 451
2025
Q3
$436K Buy
957
+54
+6% +$22K ﹤0.01% 1374
2025
Q2
$294K Buy
903
+240
+36% +$66.4K ﹤0.01% 1534
2025
Q1
$179K Sell
663
-5
-0.7% -$1.28K ﹤0.01% 1548
2024
Q4
$157K Buy
668
+55
+9% +$14.5K ﹤0.01% 1662
2024
Q3
$169K Sell
613
-13
-2% -$3.38K ﹤0.01% 1420
2024
Q2
$152K Sell
626
-107,784
-99% -$17M ﹤0.01% 1389
2024
Q1
$16.3M Buy
108,410
+107,897
+21,033% +$18M 0.02% 474
2023
Q4
$100K Buy
513
+28
+6% +$4.77K ﹤0.01% 1574
2023
Q3
$86.7K Sell
485
-2,781
-85% -$531K ﹤0.01% 1652
2023
Q2
$620K Buy
3,266
+143
+5% +$28.4K ﹤0.01% 1254
2023
Q1
$627K Sell
3,123
-1,109
-26% -$233K ﹤0.01% 1172
2022
Q4
$1.01M Sell
4,232
-2,351
-36% -$501K ﹤0.01% 1083
2022
Q3
$1.3M Sell
6,583
-5,617
-46% -$1.07M 0.01% 903
2022
Q2
$1.81M Buy
12,200
+11
+0.1% +$1.56K 0.01% 815
2022
Q1
$2.04M Buy
12,189
+7,382
+154% +$1.12M 0.01% 868
2021
Q4
$796K Buy
+4,807
New +$893K ﹤0.01% 1126

Other funds holding ALNY

National Bank of Canada's ALNY Position: Q1 2026 in Review

National Bank of Canada reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.3% in Q1 2026, selling an estimated $962K and leaving 63,607 shares worth $21M. The position accounts for 0.02% of the portfolio, ranked #480.

National Bank of Canada first reported a position in ALNY in Q4 2021 and has held it in 18 quarters since. The position peaked at $26.4M in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • National Bank of Canada held 63,607 shares of Alnylam Pharmaceuticals worth $21M as of Q1 2026.
  • National Bank of Canada sold 2,826 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $962K.
  • Alnylam Pharmaceuticals made up 0.02% of National Bank of Canada's portfolio in Q1 2026, its #480 holding.
  • National Bank of Canada first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • National Bank of Canada's Alnylam Pharmaceuticals position peaked at $26.4M in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.